A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia

Inclusion Criteria:

1. Ages from 4~12 years old (including 4 years or 12 years old）；

2. According to the Chinese Medical Association Ophthalmology branch: Strabismus andPediatric Ophthalmology Experts "Consensus of Amblyopia Diagnosis " (2011) as thestandard to be diagnosed as amblyopia with abnormal vision than that of age-basednorms, that is, caused by abnormal visual development due to strabismus, uncorrectedrefractive error or form deprivation, the best corrected vision acuity of single eyeor both eyes below age-based norms; Or 2 eyes' vision acuity difference larger than 2lines or more. The normal minimum limit of vision acuity for children of differentages are as the followings: The normal minimum limit of vision acuity for childrenaged 4 to 5 years is 0.5 (decimal vision acuity); And the normal minimum limit ofvision acuity for children aged 6 and over is 0.7(decimal vision acuity).

3. The subject's supervision is fully understand the purpose of the trial and sign aninformed consent form; And the subject can cooperate with the whole treatment andrelated eye examinations。 -

Exclusion Criteria:

1. Subjects suffered from tumors, heart disease, hypertension (blood pressure toplimitation of children aged 4 to 6 years: 110/70 mmHg, blood pressure top limitationof children aged 7 to 12 years: 120/80 mmHg), or epilepsy;

2. The subject has implanted electronic devices, such as pacemakers, etc.

3. The subject had or has a mental illness;

4. Any eye of the subject due to keratitis, conjunctivitis, internal turning eyelashesand other diseases leading to photophobia or continuing tears;

5. Subject suffered from vertigo, acrophobia or traumatic brain lesions;

6. The subject's eye has congenital glaucoma, congenital ptosis, dacryocystitis, traumaand other significant vision related lesions;

7. Subject received a masking therapy or a treatment instrument for amblyopia treatmentbefore joining this study;

8. The subject participated in other clinical trials before joining this study;

9. For safety reasons or for the benefit of patients, the researchers believe that thepatient should not participate in other conditions, such as suffering from a certainsevere heart, liver or kidney disease.